Risk of major adverse cardiovascular events, severe hypoglycemia and all-cause mortality for widely used anti-hyperglycemic dual and triple therapies in type 2 diabetes

Research output: Contribution to conference without publisher/journalConference abstract for conferenceResearchpeer-review

Original languageEnglish
Publication dateSept 2020
Number of pages1
Publication statusPublished - Sept 2020
Event56th Annual Meeting of the European Association for the Study of Diabetes (EASD) - Virtual Meeting
Duration: 21 Sept 202025 Sept 2020

Conference

Conference56th Annual Meeting of the European Association for the Study of Diabetes (EASD)
LocationVirtual Meeting
Period21/09/202025/09/2020

Cite this